Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 111.00
+10.00 (9.90%)
Apr 29, 2026, 1:30 PM CST
TPE:6919 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 38.04 | 38.04 | 44.43 | 38.93 | 12.82 | 12.34 | Upgrade
|
| Revenue Growth (YoY) | -6.00% | -14.40% | 14.13% | 203.68% | 3.90% | 19.22% | Upgrade
|
| Cost of Revenue | 11.52 | 11.52 | 13.67 | 11.46 | 3.21 | 3.11 | Upgrade
|
| Gross Profit | 26.52 | 26.52 | 30.76 | 27.47 | 9.61 | 9.23 | Upgrade
|
| Selling, General & Admin | 90.21 | 83.21 | 97.79 | 36.95 | 34.21 | 59.35 | Upgrade
|
| Research & Development | 661.89 | 650.54 | 650.12 | 503.99 | 295.02 | 180.62 | Upgrade
|
| Operating Expenses | 752.1 | 733.74 | 747.91 | 540.94 | 329.23 | 239.97 | Upgrade
|
| Operating Income | -725.57 | -707.22 | -717.14 | -513.47 | -319.62 | -230.73 | Upgrade
|
| Interest Expense | -0.11 | -0.16 | -0.33 | -0.5 | -0.67 | -2.9 | Upgrade
|
| Interest & Investment Income | 268.08 | 233.07 | 74.21 | 17.42 | 5.19 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 173.8 | 122.7 | 38.63 | -1.03 | 14.23 | -1.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.3 | -0.31 | 15.81 | 9.12 | 14.83 | 10.34 | Upgrade
|
| EBT Excluding Unusual Items | -284.11 | -351.92 | -588.83 | -488.46 | -286.05 | -224.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.11 | - | Upgrade
|
| Pretax Income | -284.11 | -351.92 | -588.83 | -488.46 | -286.16 | -224.26 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | 0.03 | Upgrade
|
| Net Income | -284.11 | -351.92 | -588.83 | -488.46 | -286.16 | -224.29 | Upgrade
|
| Net Income to Common | -284.11 | -351.92 | -588.83 | -488.46 | -286.16 | -224.29 | Upgrade
|
| Shares Outstanding (Basic) | 1,546 | 1,543 | 1,430 | 1,239 | 1,171 | 920 | Upgrade
|
| Shares Outstanding (Diluted) | 1,546 | 1,543 | 1,430 | 1,239 | 1,171 | 920 | Upgrade
|
| Shares Change (YoY) | 5.54% | 7.94% | 15.40% | 5.77% | 27.35% | 23.49% | Upgrade
|
| EPS (Basic) | -0.18 | -0.23 | -0.41 | -0.39 | -0.24 | -0.24 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.23 | -0.41 | -0.39 | -0.24 | -0.24 | Upgrade
|
| Free Cash Flow | -348.01 | -442.43 | -532.31 | -432.54 | -256.93 | -125.6 | Upgrade
|
| Free Cash Flow Per Share | -0.23 | -0.29 | -0.37 | -0.35 | -0.22 | -0.14 | Upgrade
|
| Gross Margin | 69.72% | 69.72% | 69.23% | 70.56% | 74.94% | 74.83% | Upgrade
|
| Operating Margin | -1907.45% | -1859.31% | -1613.95% | -1318.88% | -2493.17% | -1869.95% | Upgrade
|
| Profit Margin | -746.88% | -925.20% | -1325.18% | -1254.64% | -2232.10% | -1817.76% | Upgrade
|
| Free Cash Flow Margin | -914.89% | -1163.16% | -1197.97% | -1111.01% | -2004.12% | -1017.90% | Upgrade
|
| EBITDA | -702.48 | -684.64 | -695.71 | -493.68 | -302.36 | -214.49 | Upgrade
|
| D&A For EBITDA | 23.09 | 22.58 | 21.43 | 19.79 | 17.26 | 16.24 | Upgrade
|
| EBIT | -725.57 | -707.22 | -717.14 | -513.47 | -319.62 | -230.73 | Upgrade
|
| Advertising Expenses | - | - | - | 0.06 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.